Easton Capital is raising a pair of life sciences funds. One will be
a classic 10-year fund targeted to raise $100-$200 million for biotech
investment. The other will aim for $50-$75 million for investment in biotech
and medical device companies that will produce returns within a 3-5 year time
frame.
Managing Partner John Friedman
refers to the second